Head and Neck Tumors

1.	Korrelation von TP53 Mutation und Stk15 Polymorphismus in Bezug auf Überleben von Patienten mit Plattenepithelkarzinomen im Kopf-Hals-Bereich
	Santhirasegaram, Karthiga 2015-01-01
	Plattenepithelkarzinome des Kopf-Hals-Bereiches stehen weltweit an sechster Stelle aller Tumorentitäten mit einer schlechten 5-Jahres-Überlebensrate. Es sollte nun der Stk15 Polymorphismus und TP53 Mutationen hinsichtlich ihrer Prognoserelevanz untersucht werden. Es zeigte sich, dass TP53 Mutationen deutlich häufiger in Tumorgeweben zu finden waren als im Normalgewebe. Auch der heterozygote Stk15 Polymorphismus Phe/Ile lag im Tumor häufiger vor. Korrelationen mit dem Gesamtüberleben und klini...
	DRIVER-DE
2.	Why Do Head and Neck Cancer Patients Visit the Emergency Department?
	Tang, Pei-Ling 2015-08-01
	PMID:26004739
	SCIGOV-EN
3.	Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin : Results from the DAHANCA 18 phase II study
	Bentzen, Jens 2015-01-01
	PURPOSE/OBJECTIVE: A phase II clinical trial evaluating the feasibility and outcome of treating locally advanced head and neck squamous cell carcinoma (HNSCC) with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. MATERIAL AND METHODS: A total of 227 patients with stage III or IV HNSCC of the larynx, oropharynx, hypopharynx, or oral cavity where included between January 2007 and December 2010. The prescribed radiotherapy (RT) dose was 66-68 Gy in 2 Gy fractions, 6 F/W. The hypoxic radiosensitiser nimorazole was given orally at a dose of 1200 mg/m(2) before each fraction. Concomitant cisplatin (40 mg/m(2)) i.v. was given once a week for a maximum of six cycles. Outcome data were evaluated in terms of loco-regional tumour control (LRC), event-free survival (EFS) and overall survival (OS). Morbidity data were evaluated based on the DAHANCA routine registration. Human papillomavirus (HPV)-status was estimated by immunohistochemical staining of p16. RESULTS: Included were 178 (78%) men and 49 (22%) women with a median age of 57 years. All except five patients received RT as prescribed. At least five series of cisplatin was given to 164 (72%) of the patients, and 149 patients (66%) received the full dose of nimorazole. The five-year actuarial LRC, EFS and OS rates were 80%, 67% and 72%, respectively. The LRC rates according to site were: oropharynx: 88%, larynx: 77%, hypopharynx 72% and oral cavity 49%, respectively. HPV/p16 staining was obtained in 141 of the 150 oropharyngeal cancers. Of these, 112 (79%) were p16 pos and 29 (21%) were p16 neg. LRC for the p16 neg oropharyngeal cancers was poorer than for the p16 pos (74% vs. 91%; p = 0.02). Tube feeding during treatment was necessary for 146 (64%) patients. At 12 months this number was reduced to 6%. CONCLUSION: The treatment was tolerable in this cohort of locally advanced HNSCC patients. Acute and late toxicity was comparable to similar studies of chemoradiotherapy, and the outcome superior to the data reported in the literature. This strongly indicates that RT of advanced head and neck cancer must include as well hypoxic modification, accelerated fractionation as chemoradiotherapy to yield optimal outcome.
	DEFFRD-EN
4.	Vitamin and carotenoid intake and risk of head-neck cancer subtypes in the Netherlands Cohort Study.
	de Munter, Leonie 2015-08-01
	PMID:26156734
	SCIGOV-EN
5.	Erratum to: Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck.
	Dornoff, Nicolas 2015-08-01
	PMID:26238802
	SCIGOV-EN
6.	Analysis of Dysphagia Patterns Using a Modified Barium Swallowing Test Following Treatment of Head andNeck Cancer
	Lee SY 2015-08-07 02:16:05.0
	Full Text Available
	WWS-SYNAPSE
7.	A Lethal Sequelae of Spinal Infection Complicating Surgery and Radiotherapy for Head and Neck Cancer
	Cheung JP 2015-08-07 02:16:05.0
	Full Text Available
	WWS-SYNAPSE
8.	A Lethal Sequelae of Spinal Infection Complicating Surgery and Radiotherapy for Head and Neck Cancer.
	Cheung, Jason Pui Yin 2015-08-01
	Patients who have undergone neck dissection and radiotherapy are at risk of cervical spine infections. Furthermore, previous radiotherapy and cervical spine infections can lead to fistula formation to the subarachnoid space and intracranial infection. This report discusses the serious consequences of a missed cervical spine infection including cerebrospinal fluid fistula formation and persistent central nervous system infection, and serves as a reminder to clinicians of the possible association between cervical spine infections and prior head and neck surgery and radiotherapy. In all such cases, the posterior pharyngeal wall should be inspected during follow-up. Despite the appearance of an intracranial infection, the cervical spine should be investigated, especially if the response to appropriate antibiotics is suboptimal. PMID:26240724
	SCIGOV-EN
9.	Carnitine is associated with fatigue following chemoradiotherapy for head and neck cancer.
	Endo, Kazuhira 2015-08-01
	PMID:25828505
	SCIGOV-EN
10.	American Academy of Otolaryngology: head and neck surgery foundation clinical practice guideline on acute otitis externa 2014.
	Prentice, Philippa 2015-08-01
	PMID:26187983
	SCIGOV-EN
11.	Views of general practitioners and head and neck surgeons on the referral system for suspected cancer: a survey.
	Bethell, G S 2015-08-01
	PMID:26235148
	SCIGOV-EN
12.	Obstructive Sleep Apnea and Fatigue in Head and Neck Cancer Patients.
	Zhou, Jessica 2015-08-01
	There is a systematic relationship between fatigue, sleep, and decreased quality of life in cancer patients, with notably poor sleep quality among many head and neck cancer patients during and after treatment. An often overlooked cause of sleep disturbance in this patient population is obstructive sleep apnea (OSA). This review explores the current literature on the prevalence and clinical correlates of OSA, management outcomes, and data on cytokine-mediated fatigue in OSA. OSA appears to be prevalent in head and neck cancer patients, both at baseline and after treatment, especially with multimodality therapy including radiation therapy. Predictors of developing OSA include larger tumor size and hypopharynx or larynx primary site. There is evidence that the level of fatigue seen in these patients is not necessarily correlated with the severity of their OSA. Current research highlights the role of proinflammatory cytokines, which can also be synergistically activated by radiation therapy, as mediators of fatigue. Primary management of OSA consists of continuous positive airway pressure. Although continuous positive airway pressure has been shown to improve clinical symptoms, compliance with its use remains a problem and will be an area of future research. PMID:24762708
	SCIGOV-EN
13.	Perception of Shame in Otolaryngology-Head and Neck Surgery Training.
	McMains, Kevin Christopher 2015-08-01
	PMID:26243025
	SCIGOV-EN
14.	PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
	van Dijk, Laura K 2015-08-01
	PMID:26242487
	SCIGOV-EN
15.	Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI.
	Schaarschmidt, Benedikt Michael 2015-08-01
	PMID:26243264
	SCIGOV-EN
16.	Fusobacterium necrophorum and other Fusobacterium spp. isolated from head and neck infections: A 10-year epidemiology study in an academic hospital.
	Yusuf, Erlangga 2015-08-01
	PMID:25988544
	SCIGOV-EN
17.	Analysis of the Integration of Human Papillomaviruses in Head and Neck Tumors in Relation to Patients' Prognosis.
	Vojtechova, Zuzana 2015-08-01
	PMID:26239888
	SCIGOV-EN
18.	Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
	Sakashita, Tomohiro 2015-08-01
	PMID:25814008
	SCIGOV-EN
19.	Recent Updates in Cancer Immunotherapy
	Chung MK 2015-08-07 02:16:05.0
	Full Text Available
	WWS-SYNAPSE
20.	A Case of Cochlear Implantation in Neurofibromatosis Type II
	Oh SJ 2015-08-07 02:16:05.0
	Full Text Available
	WWS-SYNAPSE